Domenico Inzitari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Domenico Inzitari has a total of 225 co-authors. Here are the top co-authors by number of shared publications:
Giovanni Pracucci
NEUROFARBA Department, University of Florence, v.le Pieraccini 6, 50139 Florence, Italy
8 shared publications- Leonardo Pantoni
Neuroscience Research Center, Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy
5 shared publications - Antonio Di Carlo
Institute of Neuroscience, Italian National Research Council, Florence, Italy
4 shared publications Anna Maria Basile
3 shared publicationsAnna Poggesi
Department of Neurological and Psychiatric Sciences, University of Florence, Viale Morgagni 85, 50134 Firenze, Italy
3 shared publications- Frederik Barkhof
Amsterdam UMC, Location VUmc
3 shared publications
Latest Publications
- 1 November 2015
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 24 (11) , 2588-2595
De novo Diagnosis of Fabry Disease among Italian Adults with Acute Ischemic Stroke or Transient Ischemic Attack
- 1 November 2015
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 24 (11) , 2588-2595
De novo Diagnosis of Fabry Disease among Italian Adults with Acute Ischemic Stroke or Transient Ischemic Attack
- 9 November 2011
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 83 (3) , 268-274
Impaired vasoreactivity in mildly disabled CADASIL patients
Background and purpose CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy) is a rare genetic disease caused by NOTCH3 gene mutations. A dysfunction in vasoreactivity has been proposed as an early event in the pathogenesis of the disease. The aim of this study was to verify whether endothelium dependent and/or independent function is altered in CADASIL patients with respect to controls. Methods Vasoreactivity was studied by a non-invasive pletismographic method in 49 mildly disabled CADASIL patients (30–65 years, 58% male, Rankin scale ≤2) and 25 controls. Endothelium dependent vasodilatation was assessed by reactive hyperaemia (flow mediated dilation–peripheral arterial tone (FMD-PAT)) and endothelium independent vasoreactivity by glyceryl trinitrate (GTN) administration (GTN-PAT). Results Patients and controls showed comparable age, gender and cardiovascular risk factor distribution. GTN-PAT values were significantly lower in CADASIL patients (1.54 (1.01 to 2.25)) than in controls (1.89 (1.61 to 2.59); p=0.041). FMD-PAT scores did not differ between patients and controls (1.88 (1.57 to 2.43) vs 2.08 (1.81 to 2.58); p=0.126) but 17 CADASIL patients (35%) had FMD-PAT scores below the fifth percentile of controls. FMD-PAT and GTN-PAT values correlated both in controls (ρ=0.648, pConclusions The impaired vasoreactivity observed in CADASIL patients highlights the fact that both endothelial and smooth muscle functional alterations may already be present in mildly disabled subjects. The improvement in vascular function could be a new target for pharmacological trials in CADASIL patients.
- 9 November 2011
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 83 (3) , 268-274
Impaired vasoreactivity in mildly disabled CADASIL patients
Background and purpose CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy) is a rare genetic disease caused by NOTCH3 gene mutations. A dysfunction in vasoreactivity has been proposed as an early event in the pathogenesis of the disease. The aim of this study was to verify whether endothelium dependent and/or independent function is altered in CADASIL patients with respect to controls. Methods Vasoreactivity was studied by a non-invasive pletismographic method in 49 mildly disabled CADASIL patients (30–65 years, 58% male, Rankin scale ≤2) and 25 controls. Endothelium dependent vasodilatation was assessed by reactive hyperaemia (flow mediated dilation–peripheral arterial tone (FMD-PAT)) and endothelium independent vasoreactivity by glyceryl trinitrate (GTN) administration (GTN-PAT). Results Patients and controls showed comparable age, gender and cardiovascular risk factor distribution. GTN-PAT values were significantly lower in CADASIL patients (1.54 (1.01 to 2.25)) than in controls (1.89 (1.61 to 2.59); p=0.041). FMD-PAT scores did not differ between patients and controls (1.88 (1.57 to 2.43) vs 2.08 (1.81 to 2.58); p=0.126) but 17 CADASIL patients (35%) had FMD-PAT scores below the fifth percentile of controls. FMD-PAT and GTN-PAT values correlated both in controls (ρ=0.648, pConclusions The impaired vasoreactivity observed in CADASIL patients highlights the fact that both endothelial and smooth muscle functional alterations may already be present in mildly disabled subjects. The improvement in vascular function could be a new target for pharmacological trials in CADASIL patients.
- 6 July 2010
- Published by SAGE Publications in International Journal of Stroke
- Vol. 5 (4) , 306-318
A Critical Review of Aspirin in the Secondary Prevention of Noncardioembolic Ischaemic Stroke
Both secondary prevention (such as lifestyle modifications, pharmacotherapy or surgery) and an understanding of the influence of risk factors (including the different aetiologic mechanisms of cerebral ischaemia) play a pivotal role in reducing the burden of recurrent stroke. Regarding the types of preventative treatments available, variations exist across all clinical studies, including differences in target populations (including the type of cerebral ischaemia), risk factors, length of follow-up, drop-out rates and outcomes, which makes translating the results of clinical trials to individual patients difficult. However, with such limitations in mind, this critical albeit nonsystematic review, which compared aspirin with other antiplatelets and in combination with other drugs, showed that the benefit from aspirin treatment is consistently shown in ischaemic stroke, while harms are limited. Furthermore, no definite superiority is apparent across different antiplatelet therapies. Dual antiplatelet regimens may expose to a slight but measurable higher risk of haemorrhagic complications, perhaps in selective groups of patients (i.e. those with severe small-vessel disease or in selective racial groups). Based on our analysis, the indication of aspirin as the first-line choice, also recommended by several acknowledged international or national guidelines, may be confirmed. However, the complex nature of patients at risk of recurrent ischaemic stroke necessitates a comprehensive approach, which should be driven by the primary care physician, whose role is central to successful actions for secondary stroke prevention.
- 6 July 2010
- Published by SAGE Publications in International Journal of Stroke
- Vol. 5 (4) , 306-318
A Critical Review of Aspirin in the Secondary Prevention of Noncardioembolic Ischaemic Stroke
Both secondary prevention (such as lifestyle modifications, pharmacotherapy or surgery) and an understanding of the influence of risk factors (including the different aetiologic mechanisms of cerebral ischaemia) play a pivotal role in reducing the burden of recurrent stroke. Regarding the types of preventative treatments available, variations exist across all clinical studies, including differences in target populations (including the type of cerebral ischaemia), risk factors, length of follow-up, drop-out rates and outcomes, which makes translating the results of clinical trials to individual patients difficult. However, with such limitations in mind, this critical albeit nonsystematic review, which compared aspirin with other antiplatelets and in combination with other drugs, showed that the benefit from aspirin treatment is consistently shown in ischaemic stroke, while harms are limited. Furthermore, no definite superiority is apparent across different antiplatelet therapies. Dual antiplatelet regimens may expose to a slight but measurable higher risk of haemorrhagic complications, perhaps in selective groups of patients (i.e. those with severe small-vessel disease or in selective racial groups). Based on our analysis, the indication of aspirin as the first-line choice, also recommended by several acknowledged international or national guidelines, may be confirmed. However, the complex nature of patients at risk of recurrent ischaemic stroke necessitates a comprehensive approach, which should be driven by the primary care physician, whose role is central to successful actions for secondary stroke prevention.
- Open Access
Changes in white matter as determinant of global functional decline in older independent outpatients: three year follow-up of LADIS (leukoaraiosis and disability) study cohort
Objective To assess the impairment in daily living activities in older people with age related changes in white matter according to the severity of these changes. Design Observational data collection and follow-up of a cohort of older people undergoing brain magnetic resonance imaging after non-disabling complaints. Setting 11 European centres. Participants 639 non-disabled older patients (mean age 74.1 (SD 5.0), 45.1% men) in whom brain magnetic resonance imaging showed mild, moderate, or severe age related changes in white matter (Fazekas scale). Magnetic resonance imaging assessment also included cerebral infarcts and atrophy. Main outcome measure Transition from no disability (defined as a score of 0 or 1 on the instrumental activities of daily living scale) to disability (score ≥2) or death over three year follow-up. Secondary outcomes were incident dementia and stroke. Results Over a mean follow-up period of 2.42 years (SD 0.97, median 2.94 years), information on the main outcome was available for 633 patients. The annual rate of transition or death was 10.5%, 15.1%, and 29.5%, respectively, for patients with mild, moderate, or severe age related changes in white matter (Kaplan-Meier log rank test PConclusion The three year results of the LADIS study suggest that in older adults who seek medical attention for non-disabling complaints, severe age related changes in white matter independently and strongly predict rapid global functional decline.
Open AccessChanges in white matter as determinant of global functional decline in older independent outpatients: three year follow-up of LADIS (leukoaraiosis and disability) study cohort
Objective To assess the impairment in daily living activities in older people with age related changes in white matter according to the severity of these changes. Design Observational data collection and follow-up of a cohort of older people undergoing brain magnetic resonance imaging after non-disabling complaints. Setting 11 European centres. Participants 639 non-disabled older patients (mean age 74.1 (SD 5.0), 45.1% men) in whom brain magnetic resonance imaging showed mild, moderate, or severe age related changes in white matter (Fazekas scale). Magnetic resonance imaging assessment also included cerebral infarcts and atrophy. Main outcome measure Transition from no disability (defined as a score of 0 or 1 on the instrumental activities of daily living scale) to disability (score ≥2) or death over three year follow-up. Secondary outcomes were incident dementia and stroke. Results Over a mean follow-up period of 2.42 years (SD 0.97, median 2.94 years), information on the main outcome was available for 633 patients. The annual rate of transition or death was 10.5%, 15.1%, and 29.5%, respectively, for patients with mild, moderate, or severe age related changes in white matter (Kaplan-Meier log rank test PConclusion The three year results of the LADIS study suggest that in older adults who seek medical attention for non-disabling complaints, severe age related changes in white matter independently and strongly predict rapid global functional decline.
- Open Access
- 8 January 2007
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 167 (1) , 81-88
Risk of Rapid Global Functional Decline in Elderly Patients With Severe Cerebral Age-Related White Matter Changes
Many older people without major neurological diseases have hyperintensities in the white matter on brain magnetic resonance imaging (MRI), also called leukoaraiosis or age-related white matter changes (ARWMCs).1 In about one third of cases, these changes are of moderate to severe grade.2
- 8 January 2007
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 167 (1) , 81-88
Open AccessRisk of Rapid Global Functional Decline in Elderly Patients With Severe Cerebral Age-Related White Matter Changes
Many older people without major neurological diseases have hyperintensities in the white matter on brain magnetic resonance imaging (MRI), also called leukoaraiosis or age-related white matter changes (ARWMCs).1 In about one third of cases, these changes are of moderate to severe grade.2
- 21 December 2006
- Vol. 30, 237-44
[Prevalence of dementia in Tuscany: results from four population-based epidemiological studies].
To provide information on epidemiology of dementia in Tuscany needed to plan for dedicated health and social services. analysis of pooled baseline data from 4 population-based longitudinal studies. 4 municipalities in Tuscany. 4,056 elderly subjects enrolled in 4 longitudinal studies. age- and sex-specific dementia prevalence rates and estimated number of demented people, by degree of cognitive impairment and BADL disability in the elderly population of Tuscany. out of the evaluated subjects, 293 are demented. Prevalence of dementia increases from about 1 % in the 65-69 age group to about 28 % in the 90+ age group both among women and men. About 43% of the demented study subjects suffer from severe mental deterioration (MMSE < 14) and56% are disabled in at least one Basic Activity of Daily Living (BADL). We estimate that about 19 thousand demented elderly men and 40 thousand demented elderly women are currently living in Tuscany of whom 26 thousand severely mentally impaired and 34 thousand disabled in at least one BADL. The resulting overall dementia prevalence standardised on the Italian 65+ population is 5,3% for men and 7,7% for women. these estimates could be used as a basis for the evaluation and the planning of social and health care services dedicated to demented people.
- 21 December 2006
- Vol. 30, 237-44
[Prevalence of dementia in Tuscany: results from four population-based epidemiological studies].
To provide information on epidemiology of dementia in Tuscany needed to plan for dedicated health and social services. analysis of pooled baseline data from 4 population-based longitudinal studies. 4 municipalities in Tuscany. 4,056 elderly subjects enrolled in 4 longitudinal studies. age- and sex-specific dementia prevalence rates and estimated number of demented people, by degree of cognitive impairment and BADL disability in the elderly population of Tuscany. out of the evaluated subjects, 293 are demented. Prevalence of dementia increases from about 1 % in the 65-69 age group to about 28 % in the 90+ age group both among women and men. About 43% of the demented study subjects suffer from severe mental deterioration (MMSE < 14) and56% are disabled in at least one Basic Activity of Daily Living (BADL). We estimate that about 19 thousand demented elderly men and 40 thousand demented elderly women are currently living in Tuscany of whom 26 thousand severely mentally impaired and 34 thousand disabled in at least one BADL. The resulting overall dementia prevalence standardised on the Italian 65+ population is 5,3% for men and 7,7% for women. these estimates could be used as a basis for the evaluation and the planning of social and health care services dedicated to demented people.
- 1 December 2006
- Vol. 97 (12) , 670-8
[Neurology: the near future].
Neurological diseases are an important area of medicine, also given the high impact in terms of frequency, disabling outcomes and high costs for health systems. Part of them are related to ageing and, therefore, their frequency is expected to increase in the near future. Recent advances are consequent to the essential contribution of basic research, concerning either pathophysiology or diagnostics. Both have provided substantial advances regarding treatments, despite the fact that etiology remains often still undefined. In this review new developments regarding pathophysiology, diagnostics and treatment of main neurological diseases (Alzheimer disease, multiple sclerosis, Parkinson disease, epilepsy, and cerebrovascular disease) are discussed.
- 1 December 2006
- Vol. 97 (12) , 670-8
[Neurology: the near future].
Neurological diseases are an important area of medicine, also given the high impact in terms of frequency, disabling outcomes and high costs for health systems. Part of them are related to ageing and, therefore, their frequency is expected to increase in the near future. Recent advances are consequent to the essential contribution of basic research, concerning either pathophysiology or diagnostics. Both have provided substantial advances regarding treatments, despite the fact that etiology remains often still undefined. In this review new developments regarding pathophysiology, diagnostics and treatment of main neurological diseases (Alzheimer disease, multiple sclerosis, Parkinson disease, epilepsy, and cerebrovascular disease) are discussed.
- 1 June 2006
- Published by Springer Nature in Neurological Sciences
- Vol. 27 (S3) , s225-s227
Italian Stroke Guidelines (SPREAD): evidence and clinical practice
Evidence-based medicine’s aims are to retrieve, screen and compound the best external evidence with the experience of the physician, and to best respond to the specific medical need of each individual patient. Clinical questions are better answered when good systematic reviews of randomised trials or good randomised clinical trials are available. On the other hand, in a clinical scenario, difficulties in applying the evidence may be amplified due to variability of disease conditions, feasibility of intervention and patient’s preferences. Guidelines are recommendations, based as much as possible on evidence, aimed at supporting clinical judgement/diagnostic skills/treatment decisions in everyday practice. Guidelines may improve the quality of care received by the patient and may contribute towards better consistency of care in a definite geographical area. However, guidelines risk reducing physician skills to critically appraising the evidence. In a clinical scenario, guidelines do not always provide substantial help, especially when no conclusive evidence supports them. The Italian Stroke Guidelines (SPREAD) have contributed towards more evidence-based and better harmonised stroke care in Italy. However, the number of high grade recommendations in SPREAD is still limited. Professionals should not forget that clinical decisions often reflect several issues, not only scientific ones, including personal experience, applicability of intervention and patient’s preferences.
- 1 June 2006
- Published by Springer Nature in Neurological Sciences
- Vol. 27 (S3) , s225-s227
Italian Stroke Guidelines (SPREAD): evidence and clinical practice
Evidence-based medicine’s aims are to retrieve, screen and compound the best external evidence with the experience of the physician, and to best respond to the specific medical need of each individual patient. Clinical questions are better answered when good systematic reviews of randomised trials or good randomised clinical trials are available. On the other hand, in a clinical scenario, difficulties in applying the evidence may be amplified due to variability of disease conditions, feasibility of intervention and patient’s preferences. Guidelines are recommendations, based as much as possible on evidence, aimed at supporting clinical judgement/diagnostic skills/treatment decisions in everyday practice. Guidelines may improve the quality of care received by the patient and may contribute towards better consistency of care in a definite geographical area. However, guidelines risk reducing physician skills to critically appraising the evidence. In a clinical scenario, guidelines do not always provide substantial help, especially when no conclusive evidence supports them. The Italian Stroke Guidelines (SPREAD) have contributed towards more evidence-based and better harmonised stroke care in Italy. However, the number of high grade recommendations in SPREAD is still limited. Professionals should not forget that clinical decisions often reflect several issues, not only scientific ones, including personal experience, applicability of intervention and patient’s preferences.
- 1 April 2006
- Published by Springer Nature in Neurological Sciences
- Vol. 27 (1) , 1-2
Awareness of stroke and stroke outcomes
- 1 April 2006
- Published by Springer Nature in Neurological Sciences
- Vol. 27 (1) , 1-2
Awareness of stroke and stroke outcomes